Proteomic analysis of sera from hepatocellular carcinoma patients after radiofrequency ablation treatment

Comparative proteomic analysis was used to search for characteristic alterations in the sera of hepatocellular carcinoma (HCC) patients who had undergone curative radiofrequency ablation treatment. Serum samples collected from eight patients before and after treatment were subjected to 2‐DE. Eighty‐...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Proteomics (Weinheim) 2005-11, Vol.5 (16), p.4287-4295
Hauptverfasser: Kawakami, Takayuki, Hoshida, Yujin, Kanai, Fumihiko, Tanaka, Yasuo, Tateishi, Keisuke, Ikenoue, Tsuneo, Obi, Shuntaro, Sato, Shinpei, Teratani, Takuma, Shiina, Shuichiro, Kawabe, Takao, Suzuki, Takamasa, Hatano, Naoya, Taniguchi, Hisaaki, Omata, Masao
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Comparative proteomic analysis was used to search for characteristic alterations in the sera of hepatocellular carcinoma (HCC) patients who had undergone curative radiofrequency ablation treatment. Serum samples collected from eight patients before and after treatment were subjected to 2‐DE. Eighty‐eight protein spots differentially expressed with the treatment were selected by clustering analysis, and the proteins were identified by MS based on MALDI‐TOF/TOF analysis and public database searches. The statistical analysis suggested that four proteins decreased after treatment (pro‐apolipoprotein, α2‐HS glycoprotein, apolipoprotein A‐IV precursor, and PRO1708/PRO2044, which is the carboxy terminal fragment of albumin) and that seven proteins were increased after treatment, including leucine‐rich α2‐glycoprotein and α1‐antitrypsin. These data facilitate the identification of differentially expressed proteins that are involved in HCC carcinogenesis and provide candidate biomarkers for the development of diagnostic and therapeutic tools.
ISSN:1615-9853
1615-9861
DOI:10.1002/pmic.200401287